Stem cell transplant with special conditioning for older AML patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a gentler chemotherapy regimen before a stem cell transplant from a partially matched family donor for patients with acute myeloid leukemia (AML) who are older or have health conditions that make standard transplants risky. The goal is to help patients achieve long-term remission with fewer serious side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 60–75 years old, OR age 18–59 with health conditions that make standard transplants risky (your doctor will determine this)
- Diagnosed with acute myeloid leukemia (AML) that needs a stem cell transplant
- Cancer is in remission or nearly in remission (less than 5% leukemia cells in bone marrow)
- Have a haploidentical donor available (a family member with half-matched bone marrow)
- Heart function adequate (left ventricle pumping at least 40% of blood)
- Kidney function adequate (clearance at least 50 mL/min)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy conditioning regimen called TBF before a haploidentical stem cell transplant (using cells from a partially matched family donor) in adults ages 55–75 with acute myeloid leukemia that has responded well to initial treatment. The goal is to see if this approach helps older patients tolerate transplant and achieve long-term remission.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial studies a gentler (“micro-”) transplant approach for people ages 60–74 with acute myeloid leukemia (AML) who are in remission and cannot safely have the usual stronger transplant conditioning. It may help reduce transplant risks while keeping the leukemia under control.
This trial tests a stem cell transplant from a partially matched family member combined with donor immune cells and targeted drugs for acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to help patients who have few other options.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.